TABLE 1.
Clinical characteristics relative to the CCI risk score
| Clinical features | CCI 2 | CCI 3 | CCI ≥ 4 | P‐value |
|---|---|---|---|---|
| Number of patients (%) | 353 (78.1) | 72 (15.9) | 27 (6.0) | |
| Age (y) | ||||
| Median (range) | 53 (18‐92) | 61 (21‐86) | 73 (39‐91) | <.001 |
| Gender, number of patients (%) | ||||
| Male | 224 (63.5) | 52 (72.2) | 20 (74.1) | .23 |
| Female | 129 (36.5) | 20 (27.8) | 7 (25.9) | |
| Body weight (kg) | ||||
| Median (range) | 61 (29.2‐168.8) | 62.7 (39.0‐103.4) | 65.5 (39.5‐93.0) | .46 |
| Blast in peripheral blood (%) | ||||
| Median (range) | 0.0 (0.0‐10.5) | 0.0 (0.0‐5.0) | 0.0 (0.0‐5.0) | .1 |
| Platelet counts (× 104/μL) | ||||
| Median (range) | 47.4 (3.4‐319.0) | 49.7 (4.1‐249.4) | 34.3 (9.5‐196.9) | .29 |
| Size of spleen (cm) | ||||
| Median (range) | 0.0 (0.0‐27.0) | 0.0 (0.0‐14.0) | 0.0 (0.0‐10.0) | .03 |
| AA‐CCI, number of patients (%) | ||||
| 2 | 99 (28.1) | 0 (0.0) | 0 (0.0) | <.001 |
| 3 to 4 | 126 (35.7) | 13 (18.0) | 0 (0.0) | |
| 5 to 6 | 117 (33.1) | 37 (51.4) | 5 (18.5) | |
| 7 to 10 | 11 (3.1) | 22 (30.6) | 22 (81.5) | |
| Sokal risk score, number of patients (%) | ||||
| Low | 166 (47.0) | 30 (41.7) | 10 (37) | .89 |
| Intermediate | 136 (38.5) | 29 (40.3) | 13 (48.2) | |
| High | 50 (14.2) | 13 (18.0) | 4 (14.8) | |
| Unknown | 1 (0.3) | 0 (0.0) | 0 (0.0) | |
| EUTOS long‐term survival score, number of patients (%) | ||||
| Low | 263 (74.5) | 50 (69.5) | 14 (51.9) | .15 |
| Intermediate | 69 (19.5) | 17 (23.6) | 10 (37.0) | |
| High | 21 (5.9) | 5 (6.9) | 3 (11.1) | |
| Additional chromosomal abnormality, number of patients (%) | ||||
| Absent | 334 (94.6) | 67 (93.1) | 27 (100) | .39 |
| Present | 19 (5.4) | 5 (6.9) | 0 (0.0) | |
| ECOG performance status, number of patients (%) | ||||
| 0 | 297 (84.1) | 57 (79.2) | 18 (66.7) | .09 |
| 1 | 49 (13.9) | 10 (13.9) | 8 (29.6) | |
| 2 | 6 (1.7) | 4 (5.5) | 1 (3.7) | |
| 3 | 1 (0.3) | 1 (1.4) | 0 (0.0) | |
| Selection of TKI as initial treatment, number of patients (%) | ||||
| Imatinib | 96 (27.2) | 34 (47.2) | 9 (33.3) | .003 |
| 2GTKI | 257 (72.8) | 38 (52.8) | 18 (66.7) | |
| Dasatinib | 114 (32.3) | 23 (32.0) | 7 (25.9) | |
| Nilotinib | 143 (40.5) | 15 (20.8) | 11 (40.8) | |
The P‐values were obtained from between‐group analyses. One point was added to the summed CCI scores according to each decade of age over 40 in the AA‐CCI score.
Abbreviations: 2GTKI, second‐generation tyrosine kinase inhibitor; AA‐CCI, age‐adjusted Charlson Comorbidity Index; CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group; EUTOS, European Treatment and Outcome Study; TKI, tyrosine kinase inhibitor.